US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

55.98 -1.69 (-2.93%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Announces Planned Chief Executive Officer Transition
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum ↗
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX) Beats Q2 Revenue Estimates on FILSPARI Sales Growth ↗
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX) Earns Perfect Ratings in Breakout Setup Screen ↗
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup ↗
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX) - High Growth Momentum and Technical Breakout Setup ↗
Via Chartmill
News headline image
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline ↗
Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building... 
Via MarketBeat
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript ↗
FILSPARI net sales surged 96% year-over-year, driven by strong FSGS launch demand. 
Via The Motley Fool
Topics Earnings
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Q2 Earnings Call Highlights ↗
Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record FILSPARI demand and revenue, driven by continued growth in IgA nephropathy and an early launch in focal segmental... 
Via MarketBeat
Topics Earnings
News headline image
Travere Therapeutics Reports Second Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Second Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
News headline image
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters ↗
This rare disease therapeutics specialist reported a notable insider sale amid a year of strong share price gains and pipeline progress. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings ↗
Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >